Abstract: Provided is an organic light-emitting device having good durability.

Abstract: A fused polycyclic compounds is represented by the general formula (I): wherein X1 to X18 each represent, independently of one another, a hydrogen atom, a halogen atom, a cyano group, a nitro group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aralkyl group, a substituted amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group.

Abstract: An object is to provide a new halogenated diarylamine compound serving as a source material for synthesis of a variety of diarylamine compounds and triarylamine compounds and a synthesis method of the new halogenated diarylamine compound. A halogenated diarylamine compound represented by the following general formula (G1) and a synthesis method thereof are provided. Note that a variety of diarylamine compounds and triarylamine compounds can be synthesized using the halogenated diarylamine compound represented by the following general formula (G1).

Abstract: This invention relates to deuterated aryl-anthracene compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.

Abstract: The present invention provides a method for producing a tetramine compound represented by formula (1): wherein R1, R2 and R3, which may be the same or different, each represents a hydrogen atom, a tertiary alkyl group having 4 to 8 carbon atoms, an unsubstituted aryl group or an aryl group substituted with a tertiary alkyl group having 4 to 8 carbon atoms, and n represents 3 or 4.

Abstract: Provided are a novel benzo[a]fluoranthene compound and an organic light emitting device having extremely good light emitting efficiency, extremely good luminance, and durability. The benzo[a]fluoranthene compound is represented by the following general formula (I): wherein: at least one of R11 to R22 represents Rm represented by the following general formula (i): Rm=—X1—Ar1??(i) wherein X1 represents a substituted or unsubstituted phenylene group, or a substituted or unsubstituted, divalent monocyclic heterocyclic group, and Ar1 represents one of the following groups (a) and (b): (a) a substituted or unsubstituted fused polycyclic group, and (b) a composite substituent formed by combining two or more of a benzene ring, a monocyclic heterocyclic ring, and a fused polycyclic ring, the composite substituent being permitted to have a substituent.

Abstract: The present invention provides a tetramine compound represented by the following general formula (1): wherein R1, R2 and R3, which may be the same or different, each represents a hydrogen atom, a tertiary alkyl group having 4 to 8 carbon atoms, an unsubstituted aryl group or an aryl group substituted with a tertiary alkyl group having 4 to 8 carbon atoms, and n represents 3 or 4.

Abstract: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.

Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.

Abstract: An object is to provide a light-emitting element having high light-emission efficiency by provision of a novel fluorene derivative as represented by General Formula (G1) below. In the formula, R1 to R8 independently represent any of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted biphenyl group. Further, ?1 to ?4 independently represent any of a substituted or unsubstituted arylene group having 6 to 12 carbon atoms. Furthermore, Ar1 and Ar2 independently represent any of an aryl group having 6 to 13 carbon atoms in a ring and Ar3 represents an alkyl group having 1 to 6 carbon atoms or a substituted or unsubstituted aryl group having 6 to 12 carbon atoms. J, k, m, and n each independently represent 0 or 1.

Abstract: Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease) are provided. The treatment including administering to a subject an indatraline derivative that inhibits the aggregation of ?-synuclein.

Abstract: A specified aromatic amine derivative having a naphthalene structure bonding to diphenylamino group with a substituent. An organic electroluminescence device which comprises at least one organic thin film layer comprising a light emitting layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein at least one of the organic thin film layer comprises the aromatic amine derivative singly or as its mixture component. Organic electroluminescence devices having a long lifetime and a high efficiency of light emission, and aromatic amine derivatives capable of realizing such organic EL devices are provided.

Abstract: The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6 C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2R7R8. Also provided is a pharmaceutical composition that includes one or more compounds of the present invention, and methods of therapeutically using and processes for producing such compounds and compositions.

Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.

Abstract: There is provided a benzo[a]fluoranthene compound represented by the formula (I): wherein: at least one R11 to R22 represents Rm represented by the formula (i): Rm=—Ar1—X1??(i) wherein: Ar1 represents any one of the following groups (i-a) to (i-c): (i-a) a substituted or unsubstituted phenylene group, (i-b) a substituted or unsubstituted monocyclic heterocyclic group, and (i-c) a composite substituent formed of two substituents selected from substituents corresponding to the groups (i-a) and (i-b); and X1 represents a substituted or unsubstituted alkyl group having 2 or more carbon atoms, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group; and R11 to R22 none of which is represented by Rm each represent a hydrogen atom, a halogen atom or the like, and R11 to R22 none of which is represented by Rm may be identical to or different from each other.

Abstract: Disclased is a polymeric compound having a constitutional unit represented by formula (1a), wherein ring A and ring B independently represent an aromatic hydrocarbon ring which may have a substituent; R1 represents a group represented by formula (2); and R2 represents an aryl group or a monovalent aromatic heterocyclic group which may be substituted by an alkyl group or the like. In formula (2), Ar1 to Ar3 independently represent an arylene group or a divalent group to which two or more arylene groups are attached via a single bond; Ar4 to Ar7 independently represent an aryl group or a monovalent aromatic heterocyclic group; R6 represents a hydrogen atom, an alkyl group, an aryl group or a monovalent aromatic heterocyclic group; Ar1 to Ar7 and R6 may be substituted by an alkyl group or the like; and k and kk independently represent an integer of 0 to 3, provided that at least one of k and kk represents an integer of 1 to 3.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: A fluorene-based derivative having a specific structure and an organic electroluminescence device in which an organic thin film layer comprising a single layer or plural layers including at least a light emitting layer is sandwiched between a cathode and an anode, wherein at least one layer of the organic thin film layers described above comprises the above fluorene-based derivative having a specific structure in the form of a single component or a mixed component. The organic electroluminescence device has a high luminous efficiency, and the fluorene-based derivative materializes the same.

Abstract: The invention relates to processes for preparing rasagiline mesylate that avoid the use of alcohol solvents, thereby producing rasagiline mesylate free of any alkyl mesylates, including isopropyl mesylate. The invention further relates to processes for purifying rasagiline mesylate to obtain a product free of alkyl mesylates, and to the thus obtained rasagiline mesylate.

Abstract: The present invention relates to a novel a process for the preparation of the compound of the general formula (I), wherein R1 and R2 are independently H or C1-6 alkyl, which comprises treating with a reducing agent either a compound of the general formula (II), wherein R1 and R2 have the meanings given for the compound of the formula (I), R3 is H or C1-4alkyl and Ph is phenyl, or a compound of the general formula (III), wherein R1, R2, R3 and Ph have the meanings given for the compound of the formula (II), the reducing agent being effective to cleave the benzyl moiety Ph-CH(R3)— from the benzylamino moiety PhCH(R3)NH— in the compound of the formula (II) or in the compound of the formula (III) to leave an amino group and, in addition, in the case of the compound of the formula (III), to reduce both the 2,3-double bond and the double bond joining the R1R2C— moiety to the 9-position of the benzonorbornene ring to single bonds.

Abstract: The present invention discloses novel and improved processes for preparation of sertraline hydrochloride crystalline form II. Thus, for example, sertraline free base is dissolved in isoamyl alcohol at 25-30° C., pH of the mass is adjusted to 2.0 with conc. hydrochloric acid (36%) at 25-30° C. and then stirred for 14 hours at 25-30° C. Filtered the solid and dried at 65° C. for 4 hours to give sertraline hydrochloride crystalline form II. The present invention also provides a novel process for preparation of sertraline hydrochloride crystalline form I.

Abstract: The present invention discloses novel and improved processes for preparation of sertraline hydrochloride crystalline form II. Thus, for example, sertraline free base is dissolved in isoamyl alcohol at 25-30° C., pH of the mass is adjusted to 2.0 with conc. hydrochloric acid (36%) at 25-30° C. and then stirred for 14 hours at 25-30° C. Filtered the solid and dried at 65° C. for 4 hours to give sertraline hydrochloride crystalline form II. The present invention also provides a novel process for preparation of sertraline hydrochloride crystalline form I.

Abstract: This invention relates to novel Spiro cyclopentane derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.

Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.

Abstract: The present invention relates to a material for an organic electro-optical device and an organic electro-optical device including the same. More particularly, the present invention relates to a material having thermal stability of a glass transition temperature of 120° C. or more and a thermal decomposition temperature of 450° C. or more, and being capable of providing an organic electro-optical device having high efficiency and a long life-span due to less crystallization and improved amorphous properties in a material for an organic electro-optical device. The material for an organic electro-optical device can be used singularly or as a host material in combination with a dopant, and includes an asymmetric fluorene derivative compound. An organic electro-optical device including the material for an organic electro-optical device is also provided.

Abstract: The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry I or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H or R1a and R2 or R1a and R2a together are (CH2)n with n being 1, 2, 3 or 4; R2 and R2a each independently are H, CH3, CH2F, CHF2 or CF3; R3 is H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds.

Abstract: The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.

Abstract: Provided is a trinaphthyl monoamine or a derivative thereof. Also provided is an organic electroluminescence device, wherein an organic thin film composed of one or more layers including at least a light-emitting layer is sandwiched between a cathode and an anode, and at least one layer in the organic thin film contains the trinaphthyl monoamine or a derivative thereof by itself or as a component of a mixture. Further provided is organic-electroluminescent-material-containing solution which contains a solvent and the trinaphthyl monoamine or a derivative thereof as an organic electroluminescent material.

Abstract: An aromatic amine derivative with a specified structure whose benzene ring is bonded with a cycloalkyl group. An organic electroluminescence device which comprises at least one organic thin film layer comprising a light emitting layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein at least one of the organic thin film layer comprises the aromatic amine derivative singly or in combination. The organic EL device employing the aromatic amine derivative reveals practically sufficient luminance even under low applied voltage, exhibits an enhanced efficiency of light emission, and is resistant to degrade even after a long time usage demonstrating a prolonged lifetime.

Abstract: A polymer compound comprising a constitutional unit of the formula (1), and a repeating unit of any of the formulae (2) to (4): (wherein, x3, y1, y2, z1 to z3 are 0 or 1. y3 represents an integer of 0 to 2. u represents an integer of 0 to 8. Z represents a pyrene residue, Ar1 represents an arylene group or di-valent heterocyclic group, and Ar2 represents an aryl group or mono-valent heterocyclic group.

Abstract: An aromatic amine derivative with a special structure bonding to a fused polycyclic hydrocarbon group having silyl group. An organic electroluminescence device which comprises one or more organic thin film layers comprising at least a light emitting layer sandwiched between a cathode and an anode, wherein at least one of the organic thin film layer comprises the above aromatic amine derivative singly or as its mixture component. An organic electroluminescence device having a long lifetime and an enhanced efficiency of light emission together with the aromatic amine derivatives realizing the device are provided.

Abstract: Provided are novel organic electroluminescent compounds and organic electroluminescent devices and organic solar cells comprising the same. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1): wherein, R1 through R10 cannot be hydrogen all at the same time. The organic electroluminescent compounds according to the invention exhibit high luminous efficiency and excellent color purity and life property of material, so that an OLED having very good operation life can be manufactured therefrom.

Abstract: A novel fluorene-containing compound and an organic electroluminescent device including an organic layer employing the same. The fluorene-containing compound has excellent electrical characteristics and an excellent charge transporting capability, and so can be used as a hole injecting material, hole transporting material, and/or emitting material that is suitable for all-color fluorescent and phosphorescent devices, such as red, green, blue, and white fluorescent and phosphorescent devices. Accordingly, an organic electroluminescent device employing the fluorene-containing compound has high efficiency, a low driving voltage, high brightness, and a long lifetime.

Abstract: Oral antidepressant formulation comprising an effective antidepressant amount of at least one pharmaceutically acceptable antidepressant active agent and an effective amount lower than 50 mg of acetylsalicylic acid, derivatives of acetylsalicylic acid, or diaspirin, for reducing the onset of antidepressant action.

Abstract: Methods of forming a multi walled or single walled carbon nanotube with one or more amine groups on the surface thereof are described. The method includes reacting a carbon nanotube having a hydroxyl surface group or a carboxyl surface group with ammonia in the presence of a catalyst at a temperature of about 300° C. or more.

Abstract: A process for the preparation of (R)—N-propargyl-1-aminoindane, or a salt thereof, comprising reacting 1-indanone with propargylamine, in presence of a mixture of sodium borohydride and acetic acid, to obtain N-propargyl-1-aminoindane; and its conversion into (R)—N-propargyl-1-aminoindane or a salt thereof.

Abstract: The present invention relates to aromatic amine derivatives having a specific structure; and organic electroluminescent devices comprising a cathode, an anode and one or plural organic thin film layers including at least a light emitting layer which are sandwiched between the cathode and the anode wherein at least one of the organic thin film layers contains the above aromatic amine derivatives in the form of a single substance or a component of a mixture. There are provided the organic electroluminescent devices exhibiting a long life and a high efficiency of light emission which are capable of emitting a blue light having a high color purity, as well as the aromatic amine derivatives capable of realizing such organic electroluminescent devices.

Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; ??(I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Abstract: The invention relates to processes for preparing rasagiline mesylate that avoid the use of alcohol solvents, thereby producing rasagiline mesylate free of any alkyl mesylates, including isopropyl mesylate. The invention further relates to processes for purifying rasagiline mesylate to obtain a product free of alkyl mesylates, and to the thus obtained rasagiline mesylate.

Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.

Abstract: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.

Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Abstract: It is an object of the present invention to provide a novel triarylamine polymer which is excellent in solubility and film-forming property and has improved thermal stability; a simple process for its production; and an electronic element employing it.

Abstract: Methods for treating gout flares comprising concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.

Abstract: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.

Abstract: Arylamine compounds having at least one spiro bond are provided to the layers of an electroluminescent device. The compounds act as hole transporting and luminescent host materials for both fluorescent and phosphorescent emission. Electroluminescent devices employing the arylamine compounds exhibit excellent luminous efficiency, heat resistance and device life.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: The present invention relates to aromatic amine derivatives having a specific structure in which a substituted anthracene structure is bonded to an amine structure substituted with benzene rings having substituent groups; and organic electroluminescence devices comprising a cathode, an anode and one or plural organic thin film layers having at least a light emitting layer which are sandwiched between the cathode and the anode wherein at least one of the organic thin film layers contains the above aromatic amine derivative in the form of a single substance or a component of a mixture. There are provided organic electroluminescence devices having a high luminance of light emitted and a high efficiency of blue light emission and exhibiting a long life, as well as novel aromatic amine derivatives capable of realizing such organic electroluminescence devices.

Abstract: The present invention refers to dyestuffs of the general Formula (I) wherein R, X, Y and Z are defined as given in claim 1, dyestuff mixtures and hair dye compositions comprising them, as well as a process for colouring hair.

Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same. Specifically, the organic electroluminescent compounds according to the invention are represented by Chemical Formula (1): wherein, total number of carbons in ?is from 21 to 60. The electroluminescent compounds according to the present invention are green electroluminescent compounds, of which the luminous efficiency and device lifetime have been maximized.